The CCDC185 Knockout HeLa Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the widely used HeLa host line, enabling targeted disruption of the CCDC185 gene for loss-of-function investigations. This polyclonal model offers a genetically heterogeneous pool of edited cells, facilitating robust functional genomics studies without the constraints of clonal selection. The knockout population is designed to support reproducible interrogation of CCDC185-dependent processes in a human cervical adenocarcinoma background, addressing the need for well-characterized polyclonal knockout resources in ciliary and cancer biology.
HeLa cells, originally isolated from a cervical adenocarcinoma of a 31-year-old African American woman, serve as an adherent, aneuploid, and HPV18-positive epithelial model. Their integrated HPV18 sequences drive constitutive expression of E6 and E7 oncoproteins, which inactivate p53 and pRb tumor suppressors, respectively, conferring a highly proliferative and transformed phenotype. This host background is a cornerstone in cell biology, extensively employed in studies of viral oncogenesis, cell cycle regulation, and drug response, making it an ideal chassis for CRISPR-based gene disruption to explore tumorigenic pathways.
CCDC185 encodes an uncharacterized coiled-coil domain-containing protein with emerging links to ciliogenesis and cell cycle control. It is transcriptionally regulated by ciliogenic transcription factors FOXJ1 and RFX family members, placing it within the broader ciliogenesis regulatory network. CCDC185 interacts with microtubule components (tubulins), intraflagellar transport proteins such as IFT88 and IFT140, and the BBSome complex, suggesting a structural or functional role in primary cilium assembly. Its loss-of-function is predicted to impede primary cilium formation, thereby attenuating hedgehog signaling transduction downstream of SMO and PTCH1, and reducing activation of GLI1 and GLI2 transcription factors, which drive expression of cell cycle regulatory proteins. Consequently, CCDC185 disruption may decouple ciliary-dependent signaling from proliferative control.
In the HeLa context, where HPV18 E6 and E7 already deregulate key tumor suppressors, knockout of CCDC185 introduces a specific perturbation that can unmask crosstalk between viral oncogenesis and ciliary/hedgehog signaling. Although HeLa cells exhibit low basal ciliation, environmental cues such as serum starvation can induce primary cilia, making this model suited for conditional analyses of cilium assembly and function. This polyclonal population thus enables dissection of how CCDC185 influences cytoskeletal dynamics, signal transduction, and cell proliferation in a carcinogenic background, providing insights into potential roles in cervical cancer progression and ciliopathy-related mechanisms.
This product is applicable to a wide range of experimental paradigms. Researchers can employ immunofluorescence for acetylated tubulin and ARL13B to assess cilia frequency and length changes following CCDC185 ablation, coupled with Gli-luciferase reporter assays to measure hedgehog pathway activity. Quantitative studies may include RT-qPCR and western blotting to confirm target gene disruption and downstream effects on GLI1/GLI2 expression. Functional impacts on cell behavior can be evaluated via MTS proliferation assays, migration/invasion Transwell assays, and flow cytometric cell cycle analysis. These polyclonal knockout cells are a versatile tool for functional genomics, drug target validation in ciliopathies or malignancies, and mechanistic studies linking ciliary biology to tumorigenesis. For additional information or custom requests, please contact Ascent Research.
